Unicycive Therapeutics (UNCY) – Research Analysts’ Weekly Ratings Updates

Unicycive Therapeutics (NASDAQ: UNCY) recently received a number of ratings updates from brokerages and research firms:

• 7/1/2026 – Unicycive Therapeutics had its price target lowered by Benchmark Co. from $18.00 to $13.00. They now have a “speculative buy” rating on the stock.
• 6/30/2026 – Unicycive Therapeutics had its “buy” rating reaffirmed by B. Riley Financial, Inc.. They now have a $22.00 price target on the stock.
• 6/30/2026 – Unicycive Therapeutics had its price target lowered by HC Wainwright from $22.00 to $15.00. They now have a “buy” rating on the stock.
• 6/27/2026 – Unicycive Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/13/2026 – Unicycive Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/9/2026 – Unicycive Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 6/2/2026 – Unicycive Therapeutics had its “speculative buy” rating reaffirmed by Benchmark Co.. They now have a $18.00 price target on the stock, up from $15.00.
• 5/27/2026 – Unicycive Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $22.00 price target on the stock.
• 5/13/2026 – Unicycive Therapeutics had its “buy” rating reaffirmed by Guggenheim. They now have a $37.00 price target on the stock, down from $40.00.

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.